Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
American Journal of Industrial Medicine|July 14, 2026
Occupational Zoonotic Risk at India's Human-Animal Interface: Statutory Origins and a Regulatory Pathway for the Compensation-Prevention DisconnectLaxit K Bhatt
Archives of Toxicology|September 23, 2025
Integrating immune adverse outcome pathways into vaccine safety evaluationLaxit K Bhatt, Pankaj Dwivedi, Ramchandra K Ranvir, et al.
Environmental and Molecular Mutagenesis|January 13, 2025
Assessing the impact of different solvents in the bacterial reverse mutation testSatyam N Patel, Chetan K Kajavadara, Rushikesh M Shukla, et al.
Journal of Applied Toxicology : JAT|August 29, 2025
Evaluating Solvent Safety in Chromosome Aberration Assays for Genetic ToxicologySatyam N Patel, Chetan K Kajavadara, Rushikesh M Shukla, et al.
Toxicology Mechanisms and Methods|April 28, 2025
Inhalation safety and tolerability of a novel fixed-dose combination of glycopyrronium-vilanterol powder in Wistar ratsShitalkumar D Patel, Laxit K Bhatt, Jitendra H Patel, et al.
Environmental and Molecular Mutagenesis|June 9, 2025
Comparative Analysis of TA102 and WP2 uvrA(pKM101) Strains in Detecting Nitrosamine Mutagens in the Enhanced Ames TestRushikesh M Shukla, Darshan T Valani, Chetan K Kajavadara, et al.
Regulatory Toxicology and Pharmacology : RTP|October 12, 2024
Selection of solvent and positive control concentration for enhanced Ames test conditions for N-nitrosamine compoundsChetan K Kajavadara, Satyam N Patel, Rushikesh M Shukla, et al.
Pathogens and Global Health|March 20, 2024
Immunization of laboratory animal workers: occupational health and safety aspectsLaxit K Bhatt, Jitendra H Patel, Chitrang R Shah, et al.
Environmental Toxicology and Pharmacology|July 2, 2025
Strain-specific mutagenicity of NDMA and CPNP: insights from TA1535, TA100, and WP2 uvrA (pKM101) under metabolic activationChetan K Kajavadara, Darshan T Valani, Satyam N Patel, et al.
International Journal of Toxicology|June 20, 2024
Safety Assessment of a Novel Intravenous Diclofenac Sodium Formulation Following 28-Day Repeated Administration in Wistar RatsLaxit K Bhatt, Chitrang R Shah, Jitendra H Patel, et al.
Pageof 2